2024年国际滤泡性淋巴瘤科学研讨会共识建议
该共识基于2024年淋巴瘤研究基金会滤泡性淋巴瘤科学研讨会,专家讨论了化疗在新疗法背景下的作用、早期进展对治疗顺序的影响、临床试验新终点、疾病生物学与肿瘤微环境及新疗法。报告聚焦滤泡性淋巴瘤生物学更新、一线治疗、24个月内疾病进展的作用、临床试验设计及重新定义治愈。
要点
- 专家讨论了化疗在新疗法背景下的作用及早期进展对治疗顺序的影响。
- 报告聚焦滤泡性淋巴瘤生物学、一线治疗、24个月内疾病进展、临床试验设计及重新定义治愈。
- 新型药物在研,早期临床数据令人鼓舞,但治疗与肿瘤生物学对齐及治疗顺序仍是关键临床挑战。
核心结论
- 报告聚焦滤泡性淋巴瘤生物学更新、一线治疗、24个月内疾病进展的作用、临床试验设计及重新定义治愈。
研究设计与样本
- 2024年淋巴瘤研究基金会双年度滤泡性淋巴瘤科学研讨会专家共识报告。
主要发现
- 专家讨论了化疗在新疗法背景下的作用、早期进展对治疗顺序的影响、临床试验新终点、疾病生物学与肿瘤微环境及新疗法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. Although patients with FL have high response rates to therapy, most develop increasingly resistant disease. In addition, transformation into an aggressive lymphoma is associated with unfavorable outcomes. Many novel agents are under investigation, and early clinical data are encouraging. Aligning treatment with the underlying tumor biology and sequencing of therapies remain key clinical challenges. At the Lymphoma Research Foundation's biannual 2024 Follicular Lymphoma Scientific Workshop, experts convened to discuss the role of chemotherapy in the context of new therapies, the impact of early progression on treatment sequencing, novel end points in clinical trials, disease biology and the tumor microenvironment, and new treatments on the horizon. This report focuses on updates in FL biology, first-line treatment, the role of progression of disease in 24 months, clinical trial design, and redefining cure in FL.
引用
- Merryman R, Rutherford SC, Ansell S, et al. Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop. Blood Adv. 2026. PMID: 41337699. doi:10.1182/bloodadvances.2025018079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。